Table 1 Clinical characteristics of study subjects by ND2-237 Leu/Met genotype

Age (y)*

54.5 (7.6)

53.6 (7.8)

0.245

BMI (kg/m²)*

23.1 (2.8)

23.5 (2.6)

0.103

AST (U/L)***

22 (18–27)

23 (19–27)

0.687

Elevated levels of serum AST (≥30 U/L) (%)****

18.7

18.2

0.899

ALT (U/L)***

21 (15–32)

24 (18–35)

0.471

Elevated levels of serum ALT (>30 U/L) (%)****

27.1

30.6

0.436

Elevated levels of serum ALT (≥25 U/L) (%)****

37.9

45.9

0.100

GGT (U/L) ***

42 (27–75)

47 (30–75)

0.427

Elevated levels of serum GGT (≥60 U/L) (%)****

34.7

38.8

0.384

Elevated levels of serum GGT (>51 U/L) (%)****

39.4

45.9

0.189

SBP (mmHg)**

126.1 (16.0)

125.7 (13.9)

0.614

DBP (mmHg)**

73.9 (10.5)

73.5 (9.0)

0.628

T-C (mg/dL)*

204.2 (31.5)

202.5 (31.9)

0.590

LDL-C (mg/dL)*

122.5 (30.4)

118.4 (31.4)

0.182

HDL-C (mg/dL)**

55.0 (13.6)

55.9 (15.7)

0.576

TG (mg/dL)***

112 (84–156)

113 (81–161)

0.378

FPG (mg/dL)***

97 (92–105)

97 (91–103)

0.240

Smoking status (never- or ex-/1–20 cigarettes per day/>20 cigarettes per day) (%)

59.4/27.9/12.7

58.2/27.1/14.7

0.846

Alcohol consumption (non- or ex-/occasionally/daily) (%)****

17.9/34.3/47.8

12.9/40.0/47.1

0.285

Coffee consumption (<1 cup per day/1-2cups per day/≥3 cups per day) (%)****

45.8/31.5/22.7

36.5/40.0/23.5

0.120

Subjects under antihypertensive treatment (%)****

19.9

13.5

0.089

Subjects under antidiabetic treatment (%)****

7.2

7.7

0.855

Smokers with ND2-237Leu

Smokers with ND2-237Met

N = 102

N = 71

Smoking duration (y)*

33.5 (8.5)

32.4 (7.3)

0.352